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Abstract
Introduction: Inadequate initial treatment and delayed hemodynamic stabilization (HDS) may be associated with
increased risk of death in severe sepsis patients.
Methods: In order to compare the hemodynamic efficacy and safety of 6% HES 130/0.4 and NaCl 0.9% for HDS in
patients with severe sepsis, we designed a prospective, multicenter, active-controlled, double-blind, randomized
study in intensive care units.
Results: 174 out of 196 patients reached HDS (88 and 86 patients for HES and NaCl, respectively). Significantly less
HES was used to reach HDS vs. NaCl (1,379 ±886 ml in the HES group and 1,709 ±1,164 ml in the NaCl group
(mean difference = -331± 1,033, 95% CI -640 to -21, P = 0.0185). Time to reach HDS was 11.8 10.1 hours vs. 14.3
±11.1 hours for HES and NaCl, respectively. Total quantity of study drug infused over four consecutive days, ICU
and hospital LOS, and area under the curve of SOFA score were comparable. Acute renal failure occurred in 24
(24.5%) and 19 (20%) patients for HES and NaCl, respectively (P = 0.454). There was no difference between AKIN
and RIFLE criteria among groups and no difference in mortality, coagulation, or pruritus up to 90 days after
treatment initiation.
Conclusion: Significantly less volume was required to achieve HDS for HES vs. NaCl in the initial phase of fluid
resuscitation in severe sepsis patients without any difference for adverse events in both groups.
ClinicalTrials.gov: NCT00464204
Introduction
Inadequate initial treatment and delayed hemodynamic
stabilization (HDS) may be associated with increased
risk of death in patients with severe sepsis [1]. Opti-
mized management in the first 6 hours has been
reported to significantly reduce mortality in patients
with severe sepsis and septic shock [2]. Early adequate
fluid resuscitation is a major step in the management of
severe sepsis/shock and is recommended worldwide to
improve prognosis [3]. Early restoration of intravascular
volume requires aggressive filling with crystalloids or
colloids.
A strategy that includes colloids that are able to
reduce the amount of fluid required to reach HDS could
be beneficial. However, there are concerns regarding the
safety of colloids. Some data suggest hyperoncotic col-
loids and starches with a molar substitution >0.4 may be
harmful for the kidney in patients with septic shock
[4-6]. Third generation hydroxyethyl starch (HES), the
so-called tetrastarch (molar degree of substitution 0.4
and medium molecular weight of 130 kDa) with a
reportedly improved safety profile [7,8], has led to
renewed interest in the use of HES for volume therapy.
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However, no randomized controlled trial of tetrastarch
in patients with sepsis has yet been published. The pre-
sent study was designed to determine whether lower
volume of resuscitation fluid and a shorter time to HDS
could be achieved in patients with severe sepsis treated
with 6% HES 130/0.4 vs. a control group treated with
crystalloid (NaCl 0.9%). Another objective of the present
trial was to assess the occurrence of potential adverse
effects, such as kidney dysfunction, coagulation disor-
ders, and pruritus.
Materials and methods
Study design
This prospective, multicentre, active-controlled, double-
blind, randomized, clinical study conducted in France
and Germany enrolled patients suffering from severe
sepsis. Patients received either 6% HES 130/0.4 (colloid
treatment group) or sodium chloride (NaCl 0.9%) (crys-
talloid control group), hereafter referred to as the HES
and NaCl groups. The maximum allowed dose for both
treatment groups was 50 ml/kg/day (≤8 × 500 ml bags/
day for patients weighing ≥80 kg) on the first day and
25 ml/kg/day (≤4 × 500 ml bags/day for patients weigh-
ing ≥80 kg) from the second to the fourth day. If extra
fluid was required beyond this daily volume and four-
day time period, fluid resuscitation was to be carried out
using intravenously administered crystalloids (with no
volume limitation).
The investigational and control drugs were identical in
appearance and packaging, and were labeled with rando-
mization numbers (20 bags per randomization number)
using a blinding methodology as previously described
[9]. In order to ensure sufficient hydration, additional
crystalloid infusions were requested and given in a ratio
to study medication of 1:2. The patient flow of the study
is summarized in Figure 1.
Patients
Patients aged ≥18 years, who required fluid resuscita-
tion, and who had clinically defined severe sepsis, were
included in the study [3]. The main exclusion criteria
are summarized in Table 1.
Regulatory, ethical and safety issues
The protocol and subsequent protocol amendments
were approved by the French Independent Ethics Com-
mittee (IEC), the German IEC, and the Competent
Authorities. This study was conducted to fulfill a post-
marketing requirement of HES 130/0.4 (Voluven® )
requested by the US Food and Drug Administration
(FDA). Direct written consent from individual patients
or legally acceptable representatives was obtained, as
well as deferred written informed consent according to
country-specific legal requirements.
A data safety monitoring board consisting of two inde-
pendent clinicians and one independent statistician was
established before study commencement to regularly
review de-blinded data.
Assessments
The primary endpoint was the amount of study drug
(ml) required to achieve initial HDS, defined as a mean
arterial pressure (MAP) ≥65 mmHg and at least two of
the following three parameters maintained for four
hours: central venous pressure (CVP) between 8 and 12
mmHg, urine output >2 ml/kg, and central venous oxy-
gen saturation (ScvO2) ≥70%. In addition, no increase in
the infusion of vasopressors or inotropic therapy, and
only additional study drug administration of ≤1 L were
allowed within these four hours; initial HDS was consid-
ered to be achieved at the end of this four-hour period.
The secondary objectives of this study were to
explore the efficacy of HES vs. NaCl regarding time
taken to achieve initial HDS, total quantity of study
drug infused over four consecutive days in the inten-
sive care unit (ICU), length of stay (LOS) in the ICU
and in hospital and area under the curve (AUC) of
Sequential Organ Failure Assessment (SOFA) score
from screening to day 4.
Safety variables were kidney function categorized
according to the Risk, Injury, Failure, Loss, End-Stage
Kidney Disease (RIFLE) [10] and Acute Kidney Injury
Network (AKIN) classifications [11]. Acute renal failure
(ARF) was additionally assessed as previously described
[5]. Urinary biomarkers of acute kidney injury (AKI),
namely Beta-N-acetyl-beta-D-glucosaminidase (NAG),
neutrophil gelatinase-associated lipocalin (NGAL) and
alpha-1 microglobulin [12], were assessed in a single
central laboratory during the first eight days. Laboratory
parameters and blood gas analysis were measured at
screening and then once daily until the day after last
administration of the study drug.
Statistical analysis
A sample size of 86 patients per group was required to
detect a difference of 400 ml of study medication
between the group means (90% power), with common
standard deviations of 800 ml at a significance level
(alpha) of 0.025 using a one-sided t-test. In total, 180
patients (90 per group) were randomized according to
the original protocol. The Full Analysis Set (FAS) of
patients was the primary population for statistical analy-
sis of efficacy and was defined as all randomized
patients treated with study drug who reached HDS. All
randomized patients, the intention-to-treat (ITT) popu-
lation, were analyzed for safety variables. The amount of
study drug required to achieve initial HDS (primary effi-
cacy endpoint) was tested using a one-sided t-test with
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a type I error ≤2.5%. Pearson’s c2 test was conducted to
investigate the frequency of patients not reaching HDS
within 48 hours and to analyze mortality rates, renal
dysfunction at study inclusion, ARF, and oliguria. T-
tests were used to further examine the primary efficacy
endpoint, volume of red blood cell (RBC) transfusions,
and biomarkers of AKI. A chi square (c2)-test was used
to test the non-inferiority of HES to NaCl regarding risk
of ARF. Kolmogorov-Smirnov tests were carried out to
test for normality of biomarker values. Cochran-Mantel-
Haenszel tests for trend were used to examine AKIN
and RIFLE classifications. F-tests of equal variances were
carried out to determine whether t-tests assuming equal
or unequal variances were to be applied. A forward
selection logistic regression was conducted to identify
independent variables with an effect on mortality and
test for a treatment effect (c2-test) after adjusting for
these independent variables. The statistical analysis plan
was finalized and accepted by the US Food and Drug
Administration (FDA) prior to unblinding and analysis
of the data.
Results
Patients were randomized in 24 centers (171 patients
from 21 centers in France and 25 patients from three
centers in Germany). One hundred patients were rando-
mized to HES and 96 patients were randomized to
NaCl.
Baseline characteristics
There were no significant differences between treatment
groups in demographic and baseline characteristics
(Table 2). Use of concomitant medications was compar-
able between treatment groups. Antibiotics were pre-
scribed for 100 patients (100%) and 94 patients (98%) in
the HES and NaCl groups, respectively. Most patients
received catecholamines, and fluid intake prior to rando-
mization was 35.5 ± 25.3 ml/kg in the HES group and
Figure 1 Study design.
Table 1 Exclusion criteria.
Related to pre-existing renal impairment
- Known serum creatinine >3.39 mg/dla
- Anuria lasting more than 8 hours despite fluid resuscitation
- Requirement for renal support (either continuous or discontinuous techniques, including intermittent hemodialysis, hemofiltration, and
hemodiafiltration)
Related to the potential effect on the primary endpoint
- Volume expansion with >3 L of fluid (crystalloid and/or colloid) since diagnosis of severe sepsis or refractory septic shockb
- Patients receiving norepinephrine or epinephrine at a dose >0.5 μg/kg/min or dopamine at a dose >15 μg/kg/min at the time of screening
aIf a creatinine value >3.39 mg/dl became available only after beginning treatment with the study drug, treatment could be continued if the risk/benefit ratio for
the individual patient was regarded as positive by the investigator. bPatients treated with low dose vasopressors were not excluded provided they were
responsive to fluid resuscitation as demonstrated by an individual fluid challenge.
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39.9 ± 28.6 ml/kg in the NaCl group. There were no
clinically significant differences between treatment
groups for any vital signs or hemodynamic parameters.
Severity of disease, assessed by the Simplified Acute
Physiology Score II (SAPS II), was similar for both
groups. There was no clinically significant difference
between groups in the number of patients with renal
impairment at the time of screening (62 [63.9%] and 65
[68.4%] in the HES and NaCl groups, respectively, P =
0.51).
Efficacy outcomes
The number of patients not reaching HDS within 48
hours after randomization was similar in both groups (12
and 10 in the HES and NaCl groups, respectively, P =
0.36). The efficacy analysis included 174 patients who
reached HDS (88 patients in the HES group and 86 in
the NaCl group; FAS population). Eighty-one patients
(81%) in the HES group and 83 patients (87%) in the
NaCl group completed the treatment period of four days.
Significantly less HES vs. NaCl was used to reach HDS
(1,379 ± 886 ml in the HES group and 1,709 ± 1,164 ml
in the NaCl group [Mean difference = -331 ± 1,033,
95% CI -640 to -21], P = 0.0185) (Table 3). The median
difference was 500 mL in favor of HES, and the maxi-
mum dose for initial resuscitation in both groups was
5000 mL. The cumulative volume of study drug used
over four consecutive days in the ICU was similar for
both groups (2,615 ± 1,499 and 2,788 ± 1,799 for the
HES and NaCl groups, respectively). Mean fluid balance
from start of study drug to 96 hours thereafter was 56.5
mL/kg body weight in the HES 130/0.4 group and 55.8
mL/kg body weight in the NaCl group. The time to
reach HDS was 2.5 hours shorter for the HES group
(11.8 ± 10.1 hours vs. 14.3 ± 11.1 hours for NaCl), but
the difference was not statistically significant (Table 3).
Table 2 Patient demographic and baseline characteristics.
HES 130/0.4
(n = 100)
NaCl 0.9%
(n = 96)
Gender, n (%)
- Male 64 (64) 57 59)
- Female 36 (36) 39 (41)
Age, years, mean ± SD 65.8 ± 15.4 65.9 ± 14.7
Race, n (%)
- Caucasian 96 (96) 93 97)
- Asian 1 (1) 1 (1)
- Black 1 (1) 1 (1)
- Other 2 (2) 1 (1)
Mean body mass index, kg/m2 26.2 26.0
Type of patient, n (%)
- Medical 73 (73) 70 73)
- Surgical 27 (27) 26 (27)
Renal impairment prior to screening*, n (%) 62 (63.9) 65 (68.4)
SAPS II prior to randomization, mean 50 53
SOFA at screening, mean 7.9 9.1
Fluid input prior to randomization, ml/kg body weight, mean ± SD 35.5 ± 25.3 39.9 ± 28.6
Origin of sepsis, n (%)
- Lungs 53 (53) 58 (60)
- Abdomen 24 (24) 18 (19)
- Urogenital 8 (8) 14 (15)
- Skin, bone and soft tissue 6 (6) 4 (4)
- Other 5 (5) 2 (2)
- Unknown 4 (4) 2 (2)
- Neurological system 3 (3) 2 (2)
- Ear nose and throat 2 (2) 0 (0)
Causative organism, n (%)
- Gram-negative bacteria 35 (35) 41 (43)
- Gram-positive bacteria 25 (25) 27 (28)
- Other classes 40 (40) 32 (33)
None of the differences were statistically significant; *known serum creatinine >3.39 mg/dl; SD, standard deviation; SAPS II, simplified acute physiology score;
SOFA, sequential organ failure assessment; HES, hydroxyethyl starch; NaCI, sodium chloride.
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There was no statistically significant difference
between HES and NaCl for LOS in the ICU (15.4 ± 11.1
days vs. 20.2 ± 22.2 days for HES and NaCl, respec-
tively) or LOS in the hospital (37.7 ± 26.5 days vs. 42.7
± 31.6 days for HES and NaCl, respectively) for patients
who did not die before the study ended.
Mean total SOFA score decreased from baseline and
was similar at the last available value (5.8 and 6.0 for
HES and NaCl, respectively). The AUC of the SOFA
score per day, from screening to day 4, was similar for
both groups (6.9 ± 3.3 vs. 7.6 ± 3.1 for HES and NaCl,
respectively). There were no clinically significant differ-
ences between treatment groups for any vital signs or
hemodynamic parameters.
Mortality rate until day 28 was 31/100 (31.0%) vs. 24/
95 (25.3%) for patients treated with HES or NaCl,
respectively (P = 0.37). Likewise, mortality rate up to
the end of the follow-up period (day 90) was similar
between treatments, with no treatment effect on mortal-
ity rate detected (40/99 [40%] vs. 32/95 [34%]) for HES
and NaCl, respectively (P = 0.33). After adjusting for
SAPS II, the treatment had no statistically significant
effect on mortality until the end of the follow-up period
(P = 0.1721). A forward selection logistic regression ana-
lysis identified SAPS II, site of sepsis, causative organism
and age to be associated with mortality, while fluid
treatment had no significant effect (P = 0.3754).
Safety outcomes
Safety outcomes were assessed for the ITT patient
population (196 patients) (Figure 1).
Treatment groups were comparable for the RIFLE and
AKIN classifications (P = 0.81 and 0.59, respectively)
and for the number of patients presenting with ARF at
any time after screening (24 [24.5%] vs. 19 [20%] for
HES and NaCl, respectively, P = 0.454; Table 4). The
course of mean serum creatine (SCr) over time was also
similar in both groups (Figure 2). The mean highest SCr
values were 1.757 ± 1.230 and 1.722 ± 1.195 mg/dl (155
± 109 and 152 ± 106 µmol/l, respectively) for HES and
NaCl, respectively (P = 0.93). Urinary biomarkers indi-
cated that HES did not induce AKI (Table 5), with
neither tubular nor glomerular function significantly
affected. Differences between treatment groups were not
significantly different for coagulation factors. In
addition, there were no significant differences between
HES and NaCl for number of patients receiving RBC
transfusion or volumes of RBC transfusions (Table 6).
Overall, three patients in the HES group (3.0%) and
three patients in the NaCl group (3.1%) experienced
itching. Eleven patients (11%) in the HES group and 16
patients (16.7%) in the NaCl group had nosocomial
infections. At no time, did the Data & Safety Monitoring
Board recommend the study to be put on hold or enrol-
ment to be discontinued due to safety issues related to
the study medication.
Discussion
This is the first randomized, controlled, prospective,
multicentre, double-blind study of 6% HES 130/0.4 in
patients suffering from severe sepsis. The significantly
lower volume to achieve initial HDS vs. NaCl confirms
the good volume expansion effect of 6% HES130/0.4
[13]. The safety profile of HES is an ongoing matter of
debate. Several factors should be considered when asses-
sing potential drawbacks of HES: the type of HES (con-
centration, molar substitution, molecular weight, and
C2/C6 ratio) and daily and cumulative doses used,
underlying baseline kidney dysfunction, the case mix
(surgery, trauma, or sepsis), and ensuring patients are
sufficiently hydrated.
There have been initial concerns regarding the nega-
tive effect of older HES products on kidney function
after renal transplant [14]. More recent studies with
third generation HES have not confirmed this effect on
kidney function [15,16]. For patients with sepsis receiv-
ing older HES products for fluid resuscitation, two ran-
domized studies have documented an alteration of renal
function [5,6]. In the first study, a randomized, multi-
centre study including 129 septic shock patients,
patients resuscitated with 6% HES 200/0.62 had a higher
incidence of ARF vs. patients treated with gelatin (42%
vs. 23%, P < 0.03) [5]. The volumes received and the
levels of baseline creatinine before vascular filling in the
two treatment arms, however, were different, thus ren-
dering a head-to-head comparison difficult. Nonetheless,
multivariate analysis showed that using 6% HES 200/
0.62 was an independent risk factor for secondary for-
mation of renal insufficiency. In the second study, a
multicenter, two-by-two factorial trial including 537
Table 3 Efficacy outcomes.
HES 130/0.4
(n = 88)
NaCl 0.9%
(n = 86)
p
Mean volume of study drug used, ml (SD) 1,379 (886) 1,709 (1,164) 0.0185
Mean time to initial HDS, hours (SD) 11.8 (10.1) 14.3 (11.1) NS
Number of patients prescribed intravenous catecholamines (%) 88 (88.0) 87 (90.6) NS
HDS, hemodynamic stabilization; SD, standard deviation; HES, hydroxyethyl starch; NaCI, sodium chloride; NS, not significant.
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Table 4 Number of patients by the AKIN and RIFLE classifications
Worst AKIN stage HES 130/0.4 (n = 100)na (nb) (%)c NaCl 0.9% (n = 96)na (nb) (%)c
None 100 (52) (52.0) 96 (52) (54.2)
AKIN Stage 1 100 (21) (21.0) 96 (21) (21.9)
AKIN Stage 2 100 (5) (5.0) 96 (6) (6.3)
AKIN Stage 3 100 (22) (22.0) 96 (17) (17.7)
P value of test for trend 0.5857
Worst RIFLE component
None 100 (77) (77.0) 96 (73) (76.0)
Risk 100 (13) (13.0) 96 (11) (11.5)
Injury 100 (4) (4.0) 96 (5) (5.2)
Failure 100 (5) (5.0) 96 (7) (7.3)
Loss 100 1 (1.0) 96 (0) (0.0)
End-stage kidney disease 100 0 (0.0) 96 (0) (0.0)
P value of test for trend 0.8082
The AKIN classification was based on serum creatinine values and renal replacement therapy.. Urine output criteria were ignored. The RIFLE classification was
based on serum creatinine values. Urine output criteria were ignored. aNumber of evaluable patients (those for whom a score could be determined); bnumber of
patients analysed; cpercentages based on the number of evaluable patients; AKIN, Acute Kidney Injury Network; RIFLE, risk, injury, failure, loss, end-stage kidney
disease; HES, hydroxyethyl starch; NaCI, sodium chloride.
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patients with severe sepsis, resuscitation with a hyperon-
cotic 10% HES 200/0.5 given at very high cumulative
volumes, was associated with higher rates of ARF and
RRT vs. Ringer’s lactate [6]. Basic hydration therapy has
been criticized as being insufficient in both these trials
and in the second study almost 80% of patients were
randomized after successful initial HDS. Whether or not
the association between ARF and the liberal infusion of
the hyperoncotic HES preparation was cause or effect
remains elusive.
In the current study, the number of patients present-
ing with ARF, defined as doubling of the baseline creati-
nine value or need for RRT, was similar for 6% HES
130/0.4 and NaCl 0.9% (24.5% vs. 20%, respectively).
Treatment groups were also comparable for the AKIN
and RIFLE classifications. Likewise, results from three
urinary biomarker analyses confirmed that 6% HES 130/
0.4 did not induce AKI, because neither the tubular, nor
the glomerular function was affected. In addition, there
was no statistically significant treatment difference in
median change in SCr from baseline or peak post-base-
line SCr. These findings are in agreement with a recent
observational study in patients with severe sepsis or sep-
tic shock, which did not find an association of HES 130/
0.4 with RRT or renal dysfunction [17].
The fact that 6% HES 130/0.4 has a good renal safety
profile [18-22] was recently confirmed in a randomized
trauma study [23]. Even though very high volumes of
HES 130/0.4 (approximately 70ml/kg) were infused dur-
ing initial resuscitation, the incidence of renal dysfunc-
tion was lower in the HES group vs. patients treated
with NaCl 0.9%. Patients with severe underlying kidney
failure were excluded from the present study. However,
importantly, in a pharmacokinetic study in which 500
ml 6% HES 130/0.4 was administered to each of 19
patients with pre-existing renal insufficiency of variable
Table 5 Mean urinary biomarkers of acute kidney injury as a ratio to urinary creatinine.
Mean (SD)
Treatment group Baseline Until HDSa Day 1 Day 2 Day 3 Day 4 Day 8b Lastc
Alpha-1-microglobulin/urinary creatinine, g/mmol
HES 130/0.4 17.8 (21.0) 18.1 (14.8) 18.3 (16.0) 19.4 (20.3) 19.6 (20.5) 17.2 (14.4) 13.4 (14.9) 19.9 (22.7)
NaCI 0.9% 12.3 (12.9) 17.2 (18.0) 17.8 (17.1) 16.9 (15.0) 16.7 (14.9) 16.7 (13.8) 19.5 (23.9) 19.8 (23.3)
Beta-NAG/urinary creatinine, UI/mmol
HES 130/0.4 4.9 (6.6) 4.1 (3.5) 5.0 (3.8) 7.9 (12.8) 8.1 (13.6) 5.5 (4.6) 4.5 (3.0) 6.7 (10.0)
NaCI 0.9% 4.1 (4.7) 4.2 (3.5) 6.0 (9.1) 4.7 (4.2) 4.5 (4.4) 4.2 (3.3) 5.8 (5.0) 5.7 (5.5)
NGAL/urinary creatinine, μg/mmol
HES 130/0.4 283.0 (785.1) 352.8 (710.7) 229.9 (465.5) 325.9 (1,079.0) 432.9 (1458.2) 90.9 (203.4) 24.4 (71.5) 279.0 (884.8)
NaCI 0.9% 305.5 (833.9) 244.9 (452.4) 318.7 (644.8) 149.8 (303.2) 121.1 (306.1) 112.1 (373.7) 177.8 (551.5) 212.8 (604.8)
aFirst measurement until HDS visit (i.e., data recorded at day of withdrawal were assigned to the study visit corresponding to the actual time point of
measurement); bdata recorded on Day 8; clast available post-baseline measurement; HES, hydroxyethyl starch; NaCI, sodium chloride; NAG, N-acetyl-b-D-
glucosaminidase; NGAL, neutrophil gelatinase associated lipocalin; SD, standard deviation; HDS, hemodynamic stabilization.
Table 6 Bleeding and coagulation.
HES 130/0.4(n = 100) NaCl 0.9%(n = 96) P value
Number of patients with RBC transfusions, n (%) 29 (29.0) 20 (20.8) 0.2480
Volume (ml) of RBC transfusions, n (mean ± SD, range) 100 (214 ± 358, 0 to 1,394) 96 (165 ± 354, 0 to 1,661) 0.3415
Blood loss, ml, including blood sampling and drainage, n (mean ± SD, range) 63 (10.0 ± 24.4, 0.4 to 150.7) 65 (10.5 ± 29.4, 0.2 to 207.8) NS
Coagulation parameters, median values over time INR aPTT (ratio) INR aPTT (ratio) P value
Baseline 1.3 1.2 1.3 1.2
Until HDSa 0.1 0.2 0.0 0.1
Day 1 0.0 0.1 0.0 0.1
Day 2 -0.1 0.1 -0.1 0.0
Day 3 -0.1 0.1 -0.2 0.0
Day 4 -0.2 0.1 -0.2 -0.1
Day 5 -0.1 0.0 -0.1 -0.1
Day 8b -0.1 0.0 -0.2 0.0
Lastc -0.1 0.0 -0.2 0.0
aFirst measurement until HDS visit (i.e., data recorded at day of withdrawal were assigned to the study visit corresponding to the actual time point of
measurement); bdata recorded on Day 8; clast available post-baseline measurement; RBC, red blood cell; SD, standard deviation; HDS, hemodynamic stabilization;
HES, hydroxyethyl starch; NaCI, sodium chloride.
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degree, the maximum plasma concentration of starch
and its terminal half-life were not affected by renal
insufficiency [24].
Besides the study drug, patients enrolled in the pre-
sent study received basic daily rehydration therapy with
500 ml of infused isotonic saline per two bags of study
drug. The cumulative volume of study drug was
restricted to a maximum of 4,000 ml on day 1 (50 ml/
kg) and 2,000 ml/day for days 2 to 4 (10 L in total). As
a consequence, the mean cumulative volume of 2,500 to
3,000 ml was much lower, and the duration of 6% HES
130/0.4 administration much shorter (4 days) compared
to the ‘prospective randomized multicenter study on the
influence of colloid vs. crystalloid volume resuscitation
and of intensive vs. conventional insulin therapy on out-
come in patients with severe sepsis and septic shock’
(VISEP) trial, where 38% of patients repeatedly received
more than the allowed maximum daily dose for a sec-
ond generation starch and duration of administration
was >3 weeks for 13% of the patients [6].
Apart from concerns regarding effects on kidney func-
tion, effects of different HES types on coagulation and
bleeding events have been investigated in depth. In this
regard, it is important to note that the influence on coa-
gulation of 6% HES 130/0.4 is significantly reduced vs.
older HES types. Unlike HES types with a high molar
substitution, trials with 6% HES 130/0.4 in doses of up
to 50 ml/kg body weight in cardiac surgery [22], abdom-
inal surgery [25], and up to 70 ml/kg bodyweight in
severe cranio-cerebral trauma [21] have revealed no
deterioration in coagulation. The decreased influence on
coagulation and hence decreased incidence of undesir-
able effects after 6% HES 130/0.4 vs. older products is
reflected in decreased blood loss in surgical patients,
and subsequent transfusion requirements [26]. The
results of the present study are in harmony with the lat-
ter trials and confirm that 6% HES 130/0.4 has no clini-
cally relevant impact on coagulation when used
correctly. In the VISEP trial, the component of the
SOFA score related to coagulation was more altered in
the HES group vs. crystalloids [6]. Conversely, we did
not find any differences in blood loss or RBC transfu-
sion requirements. There was no significant difference
between treatment groups for any laboratory coagula-
tion parameters.
Mortality rates were not statistically different between
treatment groups. An important finding was a difference
in initial mortality rate in the 6% HES 130/0.4 group,
possibly due to a higher rate of patients with abdominal
sepsis. This difference continued until day 90. Interest-
ingly, the pattern of mortality rates was different from
that observed in the VISEP study [6], where a non-sig-
nificant separation started after day 30. The type of
volume resuscitation used was not an independent risk
factor for mortality in our study.
Other side effects were similar between treatment
groups. In animal experiments in rats, 6% HES 130/0.4
has been shown to significantly reduce tissue storage
(75% lower) for the whole body compared with HES
200/0.5 [27]. Deposits of HES in skin have been linked
to the occurrence of pruritus [28]. Three patients in
each group experienced itching in the current study
and our results clearly demonstrate that tetrastarch
infusion as used in the present study was not linked to
itching.
This study has some limitations. First, no algorithm to
assess fluid responsiveness was used and CVP, though
still recommended by the surviving sepsis guidelines, is
known to be a poor indicator of preloading [29]. Sec-
ond, the study was not designed or powered to assess
effects on mortality. A previous study has shown a ten-
dency for reduced mortality in patients with severe sep-
sis if resuscitated with colloids vs. crystalloids [30]. The
‘crystalloid vs. hydroxyl-ethyl starch trials’ (CHEST)
study, which is using 6% HES 130/0.4, will probably set-
tle this debate [9]. Finally, though extensive biomarker
analyses are provided and objective criteria to assess
kidney function were used, effects on kidney function
were not powered to assess an effect. Besides the
CHEST study, another ongoing larger study [31] will
address this important issue.
Conclusion
The primary goal of the study was reached since HES
130/0.4 was found significantly superior to NaCl with
respect to the amount of study drug required to achieve
initial hemodynamic stability in patients suffering from
severe sepsis. As used in our study, 6% HES 130/0.4,
had no negative effects on mortality, kidney function,
coagulation, or pruritus. These results need to be con-
firmed by larger trials.
Key messages
• Significantly less HES was used to reach HDS vs.
NaCl (1,379 ± 886 ml in the HES group and 1,709 ±
1,164 ml in the NaCl group [mean difference = -331
± 1,033, 95% CI -640 to -21], P = 0.0185)
• Mortality rate until day 28 was 31/100 (31.0%) vs.
24/95 (25.3%) for patients treated with HES or NaCl,
respectively (P = 0.37). Likewise, mortality rate up to
the end of the follow up period (day 90) was similar
between treatments, with no treatment effect on
mortality rate detected (40/99 [40%] vs. 32/95 [34%])
for HES and NaCl, respectively (P = 0.33).
• Treatment groups were comparable for the RIFLE
and AKIN classifications (P = 0.81, and 0.59,
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respectively) and for the number of patients present-
ing with ARF at any time after screening (24 [24.5%]
vs. 19 [20%] for HES and NaCl, respectively, P =
0.454).
• Overall, three patients in the HES group (3.0%)
and three patients in the NaCl group (3.1%) experi-
enced itching.
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